ITV News

Improving patient care

Medical health professionals use Surgihoney ROTM to treat and prevent wound infections.

Matoke Holdings Ltd is a British biotech company helping to tackle the global challenge of antimicrobial resistance. The company is focused on developing effective wound care and infection control solutions that reduce reliance on antibiotics.

Our unique Reactive Oxygen® technology platform has been hailed as potentially the biggest breakthrough since the discovery of penicillin. It destroys a wide spectrum of bacteria, both Gram-positive and Gram-negative, including MRSA and Pseudomonas.(1,7)

Reactive Oxygen® technology can be used for prevention and therapy. It is a medical innovation that could revolutionise treatment and opens a new front in the fight against antibiotic resistance.


1. Dryden M. Lockyer G. Kordo S. Cooke J. Engineered honey: in vitro antimicrobial activity of a novel topical wound care treatment. Journal of Global Antimicrobial Resistance 2014. 10.1016/j.jgar.2014.03.006

2. Dryden MS. Hudgell. Saeed K. Dryden AWS. Brooks J. Cooke J. Surgihoney - honey wound treatment: first report of in-vitro activity and early clinical evaluation. Federation of Infection Societies. Birmingham UK,2013.

3. Dryden M. Goddard C. Madadi A. Heard M. Saeed K. Cooke J. Bioengineered Surgihoney as an antimicrobial wound dressing to prevent Caesarean wound infection: a clinical and cost-effectiveness study. British Journal of Midwifery2014;22:23-7

4. Dryden M. Tawse C. Adams J. Saeed K. Cooke J. The use of Surgihoney to prevent or eradicate bacterial colonisation in dressing oncology long vascular lines. Journal of Wound Care2014;23:338-41.

5. Cooke J. When antibiotics can be avoided in skin inflammation and bacterial colonization: a review of topical treatments. Current Opinion in Infectious Diseases 2014;27:125-9.

6. Cooke J, Dryden M, Patton T, Brennan J, Barrett J. The antimicrobial activity of prototype modified honeys that generate reactive oxygen species (ROS) hydrogen peroxide. BMC Research Notes. 2015;8(1):20. Epub 2015/01/30. doi: 10.1186/s13104-014-0960-4. PubMed PMID: 25627827; PubMed Central PMCID: PMCPMC4312449.

7. Dryden M, Milward G, Saeed K. Infection prevention in wounds with Surgihoney. Journal of Hospital Infection 2014. Oct;88(2):121-2.doi:10.1016/j.jhin.2914.07.008.Epub 2014 Aug1

8. Halstead F, Oppenheim B, Dryden M. The in vitro antibacterial activity of engineered honey (Surgihoney®) against important biofilm-forming burn wound pathogens. Poster presentation. Federation of Infection Societies. Harrogate, 2014.

9. Staples, I. Why doesn't nectar ferment. Primary Care Nursing Review, March 2014.

10. Kanta J, The role of hydrogen peroxide and other reactive oxygen species in wound healing, Acta Medica 2011.

11 Fahmida Alam, Asiful Islam, Siew Hug Gan, Ibrahim Khalil. Honey: A potential therapeutic agent for managing diabetic wounds. Evidence-based Complementary and Alternative Medicine., Oct 2014

12. Dryden M. Engineered honey to manage bacterial bioburden and biofilm in chronic wounds - abstract of presentation to European Wound Management Association, May 2015.

13. Dunnill C, Patton T, Brennan J, et al. Reactive oxygen species (ROS) and wound healing: the functional role of ROS and emerging ROS-modulating technologies for augmentation of the healing process. International Wound Journal, Dec 2015!

14. Vatansever F1, de Melo WC, Avci P, Vecchio D, Sadasivam M, Gupta A, Chandran R, Karimi M, Parizotto NA, Yin R, Tegos GP, Hamblin MR. Antimicrobial strategies centred around Reactive Oxygen™ species--bactericidal antibiotics, photodynamic therapy, and beyond FEMS Microbiol Rev. 2013 Nov;37(6):955-89. doi: 10.1111/1574-6976.12026. Epub 2013 Jul 25.

15. Halstead F, Webber M, Rauf M, Burt R, Dryden M, Oppenheim B. In vitro activity of an engineered honey, standard medical-grade honeys and antimicrobial wound dressings against biofilm-producing clinical bacterial isolates. Journal of Wound Care, Feb 2016

16. Dryden M, Dickinson A, Brooks J, Hudgell L, Saeed K, Cutting K. A multi-centre clinical evaluation of Reactive OxygenTMtopical wound gel in 114 wounds. Journal of Wound Care, March 2016.

17. The Review on Antimicrobial Resistance, chaired by Jim O’ONeill, Vaccines and alternative approaches: reducing our dependence on antimicrobials, Feb 2016

18. Khan W, Williams R, Metal A, Morgan-Jones R. Surgihoney as a novel antimicrobial coating in salvage revision total knee arthroplasty. Orthopaedic Proceedings. 2015;97-Bmo.SUPP 15 66 ISSN 1358-992X

19. Dryden M, Cooke J, Salib R, Holding R, Pender S, Brooks J. Hot Topics in Reactive Oxygen therapy:antimicrobial and immunological mechanisms, safety and clinical applications. Journal Global Antimicorbial Resistance. 2017 Feb 17. pii:S2213-7165(17)30224-3doi:10.1016/j.gar.2016.12.012

20. Dryden M, Cooke J, Salib R, Holding R, Biggs T, Salamat A, Allan R, Newby R, Halstead F, Oppenhem B, Hall T, Cox S, Grover L, Al-Hindi Z, Noval-Frazer L, Richardson M. Reactive Oxygen: a novel antimicrobial mechanism for targeting biofilm-associated infection.Journal of Global Antimicrobial Resistance. 2017 Feb 14;8:186-191.doi 10.1016/j/jgar.2016.12.006

21.Dryden M. Reactive Oxygen therapy: a novel therapy is soft tissue infection.Current Opinion in Infectious Disease2017 Apr;30(2):143-149

22. Lipsky BA, Dryden M, Gottrup F, et al. Antimicrobialstewardship in wound care: a positionpaper from theBritish Society for Antimicrobial Chemotherapy and European WoundManagement AssociationJournal of Antimicrobial Chemotherapy2016,10.1093/jac/dkw287

23. Al-Waili N, Salom K, Al-Ghamdi AA. Honey for wound healing, ulcer and burns;data supporting itsuse in clinical practice. TheScientific World Journal2011:766-87

24. Ridley M. The Times. Ourbrilliant biologists are changing the world. Dec 19,2016


25.Khan W, Williams R, Metal A, Morgan-Jones R. Surgihoney as a novel antimicrobial coating in salvage revision total knee arthroplasty. Orthopaedic Proceedings. 2015;97-B no.SUPP 15 66.ISSN 1358-992X

"There is clear benefit to having a wide array of options to prevent and treat drug-resistant infections."(17)

'The Review on Antimicrobial Resistance'
chaired by Jim O'Neill